CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
287.9 AUD +0.55% Intraday chart for CSL Limited +4.21% +0.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Australian shares inch higher; inflation data reinforces subdued rate-cut view RE
CSL Prices $1.25 Billion Corporate Bonds Offering MT
Miners, healthcare firms push Australia stocks higher RE
Australian shares fall as miners, banks weigh RE
Banks drive Australian shares to record high on firming rate-cut bets RE
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee CI
Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight MT
Australia Health Stocks to Remain at Premium to ASX200, Morgan Stanley Says MT
Australian shares skid off record highs to end lower; GDP data awaited RE
Australian shares end marginally up as energy, financials offset weak miners RE
Australian shares inch lower as banks offset commodity gains RE
Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight MT
Australian shares end slightly lower; US inflation data on tap RE
Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight MT
Australian shares flat as CSL counters gains in banks, miners RE
CSL Limited Reaffirms Group Earnings Guidance for the Fiscal Year 2024 CI
Transcript : CSL Limited, H1 2024 Earnings Call, Feb 13, 2024
CSL Ltd. Posts Rise in EPS, Revenue for Half Year FY24, Beats Estimates MT
CSL Says 1st Half Profit Rises, Boosts Dividend -- Update DJ
Australia's CSL reaffirms upbeat forecast; profit jumps RE
CSL Says 1st Half Profit Rises, Boosts Dividend DJ
Australia's CSL posts 13% rise in half-year profit RE
CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024 CI
CSL Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Australian shares end lower as healthcare, commodity stocks drag RE
Chart CSL Limited
More charts
CSL Limited (CSL) is an Australia-based biotechnology company. The Company's areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company's segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company's CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company's geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL's products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
186.8 USD
Average target price
197.8 USD
Spread / Average Target
+5.86%
Consensus
  1. Stock
  2. Equities
  3. Stock CSL Limited - Australian S.E.
  4. News CSL Limited
  5. CSL Completes $534 Million Share Purchase Plan